^
Association details:
| Biomarker: | EGFR L747P |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma
Excerpt:
Soon afterwards the patient requested EGFR genetic analysis of the cancerous tissue, and sequencing revealed the presence of the rare mutation L747P (2239-2240 TT>CC), but no other mutations were found (Figure 3). Oral gefitinib was firstly administered at a daily dose of 250 mg based on the patient’s condition, but a poor response was observed,...
